COVID-19 OUTPATIENT THERAPEUTIC TREATMENT ALGORITHM
FOR ADULTS OR PEDIATRIC PATIENTS

Requirements: age 12 and older/weighing at least 40kg with mild to moderate COVID-19 and at high risk for progression to severe disease.

PATIENT TESTED POSITIVE*

PATIENT CONSIDERED HIGH-RISK**

YES

NO***

SYMPTOM ONSET ≤7 DAYS
(FIRST DAY OF SYMPTOM ONSET IS DAY 0)

YES

NO***

<5 DAYS

BETWEEN 5 AND <7 DAYS

CONSIDER IV TREATMENT

Remdesivir

Paxlovid: first line treatment in patients without severe renal/hepatic impairment. Renal dosing adjustment for moderate renal impairment (eGFR 30-60mL/min). Choose alternative therapeutics for severe renal (eGFR <30mL/min) or hepatic (Child-Pugh Class C) impairment. Consider potential drug-drug interactions that may exclude Paxlovid use or require further medication management. Alternatives if Paxlovid is not feasible, available, or clinically indicated (listed in order of NIH guidance):

Remdesivir
Lagevrio (only for adults age 18+)

*Proof of a positive COVID-19 PCR test is not a requirement from VDH or under the EUAs for COVID-19 therapeutics; consider accepting at home test results

**CDC People with Certain Medical Conditions

***For patients who do not qualify for COVID-19 outpatient therapeutics, provide supportive care and anticipatory guidance per NIH and CDC guidelines.

1 NIH Therapeutic Management of Non-hospitalized Adults with COVID-19

RESOURCES:

✔ PAXLOVID Patient Eligibility Screening Checklist Tool for Prescribers
✔ Liverpool COVID-19 Drug Interaction Checker
✔ Fact sheet for Healthcare Providers: Emergency Use Authorization for Paxlovid